RT Journal Article
SR Electronic
T1 Nationwide SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era, 2021-2022: an Ongoing Prospective Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.22.23298889
DO 10.1101/2023.11.22.23298889
A1 Vos, Eric R.A.
A1 van Hagen, Cheyenne C.E.
A1 Wong, Denise
A1 Smits, Gaby
A1 Kuijer, Marjan
A1 Wijmenga-Monsuur, Alienke J.
A1 Kaczorowska, Joanna
A1 van Binnendijk, Robert S.
A1 van der Klis, Fiona R.M.
A1 den Hartog, Gerco
A1 de Melker, Hester E.
YR 2023
UL http://medrxiv.org/content/early/2023/11/22/2023.11.22.23298889.abstract
AB Background Repeated population-based SARS-CoV-2 serosurveillance is key in complementing other surveillance tools.Aim Assessing trends in infection- and/or vaccine-induced immunity, including breakthrough infections, among (sub)groups and regions in the Dutch population during the Variant of Concern (VOC)-era whilst varying levels of stringency, to evaluate population immunity dynamics and inform future pandemic response planning.Methods In this prospective population-based cohort, randomly-selected participants (n=9,985) aged 1-92 years (recruited since early-2020) donated home-collected fingerstick blood samples at six timepoints in 2021-2022, covering waves dominated by Alpha, Delta, and Omicron (BA.1, BA.2, BA.5). IgG antibody assessments against Spike-S1 and Nucleoprotein were combined with vaccination- and testing data to estimate infection-induced (inf) and total (infection- and vaccination-induced) seroprevalence.Results In 2021, nationwide inf-seroprevalence rose modestly from 12% since Alpha to 26% amidst Delta, while total seroprevalence increased rapidly to nearly 90%, particularly fast in vulnerable groups (i.e., elderly and those with comorbidities). Highest infection rates were noticeable in adolescents and young adults, low/middle educated elderly, non-Western, contact professions (other than healthcare), and low-vaccination coverage regions. In 2022, following Omicron emergence, inf-seroprevalence elevated sharply to 62% and further to 86%, with frequent breakthrough infections and reduction of seroprevalence dissimilarities between most groups. Whereas >90% of <60-year-olds had been infected, 30% of vaccinated vulnerable individuals had not acquired hybrid immunity.Conclusion Although total SARS-CoV-2 seroprevalence had increased rapidly, infection rates were unequally distributed within the Dutch population. Ongoing tailored vaccination efforts and (sero-)monitoring of vulnerable groups remain important given their lowest rate of hybrid immunity and highest susceptibility to severe disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Ministry of Health, Welfare and Sport (VWS) in the Netherlands.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Research Ethics Committees United (MEC-U) in the Netherlands approved the study, conformed to the principles embodied in the Declaration of Helsinki, and all participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available for researchers upon reasonable request for data sharing to the principal investigator.